Aspen Aerogels vs Hudson Technologies
ASPN and HDSN side by side, both in wholesale trade-durable goods. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ASPN and HDSN compare
Aspen Aerogels is the larger company, worth 2.5 times as much as Hudson Technologies ($463M against $185M).
Hudson Technologies grew revenue faster over the last twelve months (2.3% versus −39.3% for Aspen Aerogels).
Hudson Technologies keeps more of each dollar of sales as profit, with a net margin of −0.54% compared with −60.8% at Aspen Aerogels.
Hudson Technologies scores higher on the StockData Score (9 against 4 for Aspen Aerogels), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ASPN | HDSN |
|---|---|---|
| Size and price | ||
| Market cap | $463M | $185M |
| Share price | $5.58 | $4.40 |
| Change, 1 year | 62.7% | −38.9% |
| Change, 5 years | −91.0% | −7.6% |
| Beta (5Y) | 2.17 | 0.70 |
| Employees | 854 | 281 |
| StockData Score | ||
| Total score | 4 | 9 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.2× | 0.8× (better) |
| P/B | 2.5× | 0.8× (better) |
| EV/EBITDA | – | 36.3× |
| P/FCF | 23.2× | – |
| FCF yield | 4.3% (better) | −17.1% |
| Fair value | $4.64 | $12.25 |
| Margin of safety | −20.2% | 64.1% (better) |
| Growth | ||
| Revenue growth (TTM) | −39.3% | 2.3% (better) |
| Revenue growth, 5Y average | 22.0% (better) | 10.8% |
| Net income growth (TTM) | – | −106% |
| EPS growth (TTM) | – | −102% |
| Profitability | ||
| Gross margin | 2.4% | 21.0% (better) |
| Operating margin | −59.3% | 0.37% (better) |
| Net margin | −60.8% | −0.54% (better) |
| FCF margin | 9.3% (better) | −13.0% |
| Return on equity | −53.2% | −0.51% (better) |
| Return on invested capital | −83.0% | 0.23% (better) |
| Financial health | ||
| Debt / equity | 0.12 (better) | 0.00 |
| Current ratio | 2.10 | 3.40 (better) |
| Altman Z-score | −2.72 | 3.53 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | 9.0% |
| Shareholder yield | 0.00% | 9.0% (better) |
| Ownership | ||
| Held by institutions | 88.5% | 75.1% |
| Held by insiders | 16.8% | 14.1% |
| Insider net buying, 12 months | −$58.1M | $903K (better) |
| Short interest, % of float | 9.3% | 7.1% |
Go deeper
- ASPN stock overview
- ASPN income statement
- ASPN valuation and score
- HDSN stock overview
- HDSN income statement
- HDSN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.